Myllia Biotechnology
Company Details
Status: Private
Employees: 11-50
Location:
Wien, Austria
Type:
sample
Technology:
sample
sample
sample
sample
About: Myllia Biotechnology combines CRISPR screening with single-cell RNA sequencing, leveraging two transformative technologies to enable genetic screening for complex phenotypes. We utilize the CRISPR screening workflow to map the impact of thousands of genetic perturbations on the global transcriptome at single-cell resolution, thus effectively establishing a paradigm for next-generation CRISPR screens.
Our powerful approach has broad applications in identifying novel drug targets or elucidating unknown mechanisms of actions (MoA) of drugs. Each screening project is customized to the specific needs of our clients and we perturb cells with CRISPR KO, CRISPR interference or CRISPR activation coupled to high-content read-outs such as fitness, FACS and single-cell transcriptomics. Notably, we offer single-cell CRISPR screens (CROP-Seq) in cancer cells and primary immune cells, including primary human T cells to support biotech and pharma companies striving to develop novel CAR-T and TCR-T cell therapeutics.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Myllia Biotechnology | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.